Catalyst Pharmaceuticals Inc Stock Price, News & Analysis

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced its participation in Citi's 17th Annual BioPharma Conference on September 7-8, 2022. Chairman and CEO Patrick J. McEnany, along with the management team, will host one-on-one meetings on September 8. Catalyst is dedicated to developing and commercializing innovative medicines for rare diseases, including its recently FDA-approved drug FIRDAPSE® for Lambert-Eaton myasthenic syndrome.

FIRDAPSE is also approved for use in Canada, showcasing Catalyst's commitment to addressing unmet medical needs in rare diseases.

Catalyst Pharmaceuticals (CPRX) reported record Q2 2022 net product revenues of $53.0 million, marking a 57.7% year-over-year increase. Cash and short-term investments totaled $220.8 million with no funded debt. The company completed the acquisition of Ruzurgi® U.S. and Mexico rights, potentially extending FIRDAPSE patent protection to 2037. Catalyst forecasts full-year adjusted EBITDA between $100-105 million and expects total revenues between $195-205 million, reflecting a 38%-45% increase from 2021.

Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its Q2 2022 financial results after market close on August 9, 2022. A conference call and webcast are scheduled for August 10, 2022, at 8:30 AM ET, where management will discuss the results and provide a corporate update. The event can be accessed via the company's website, and a replay will be available for 30 days. Catalyst focuses on developing medicines for rare diseases, with its FDA-approved product FIRDAPSE^® for Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals announced a settlement with Jacobus Pharmaceutical, acquiring rights to Ruzurgi in the U.S. and Mexico. This settlement resolves patent infringement litigation where Catalyst claimed Jacobus induced infringement related to FIRDAPSE. Notably, Ruzurgi is not FDA-approved for U.S. distribution due to legal complications. Catalyst plans to continue supplying Ruzurgi to patients under investigator-sponsored INDs while focusing on the LEMS patient community. Catalyst will pay Jacobus cash and a royalty on U.S. net sales of amifampridine.

Catalyst Pharmaceuticals (Nasdaq: CPRX) announced participation in two upcoming investment conferences. CEO Patrick J. McEnany and the management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 4 PM ET, and the Jefferies Healthcare Conference on June 8, 2022, at 11 AM ET. A webcast will be available on their website, with a replay for 14 days. Catalyst focuses on developing treatments for rare diseases and has FDA-approved FIRDAPSE for Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (CPRX) reported record revenue of $43.1 million for Q1 2022, marking a 42.7% year-over-year increase. This growth is attributed to increased patient conversions to FIRDAPSE® after Ruzurgi® was removed from the U.S. market. The company affirmed its full-year revenue guidance of $195 million to $205 million, expecting a 38% to 45% revenue growth from 2021. Catalyst's cash position stands at $198 million with no debt. It continues to enhance its patent portfolio and expand treatment options for rare diseases.

Catalyst Pharmaceuticals (Nasdaq: CPRX) announced it will release its first-quarter 2022 financial results on May 10, 2022, after market close. A conference call and webcast will be hosted the next morning, May 11, 2022, at 8:30 AM ET, to discuss financial results and provide corporate updates. Catalyst focuses on developing medicines for patients with rare diseases, with its FIRDAPSE® medication approved for Lambert-Eaton myasthenic syndrome. Further details and a replay of the webcast will be available on the company's website.

Catalyst Pharmaceuticals (CPRX) reported a 2021 revenue increase of 18% YoY, reaching $141 million. The fourth quarter saw revenues of $38 million, up 24% from 2020. Catalyst anticipates 2022 revenues between $195 million and $205 million, bolstered by orphan drug exclusivity for FIRDAPSE and new patent issuances extending exclusivity to 2034. Cash and investments stand at $191 million with no funded debt. The company is actively pursuing opportunities to diversify its portfolio and will host a conference call on March 17, 2022, for further updates.

Catalyst Pharmaceuticals (CPRX) announced a favorable ruling from the Federal Court of Canada, reversing Health Canada's decision on Ruzurgi (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS). The Court found that Health Canada improperly evaluated data linked to the Innovative Drug status of FIRDAPSE, which protects its data for eight years. Catalyst expressed satisfaction with the ruling, emphasizing its commitment to making Ruzurgi accessible to LEMS patients in Canada.